Drug Detail

Drug Name Vemurafenib
Trade Name Zelboraf
Synonyms RO5185426|PLX4032
Drug Descriptions

Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of the MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma and for BRAF V600-positive Erdheim-Chester disease (FDA.gov).

DrugClasses RAF Inhibitor (Pan) 17

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
BKM120 + Vemurafenib
A-1210477 + Cobimetinib + Vemurafenib
Aldesleukin + Vemurafenib
Vemurafenib + Hydroxychloroquine
S63845 + Vemurafenib
Vemurafenib + Sorafenib
Vemurafenib + Erlotinib
Vemurafenib + Panitumumab
CDX-3379 + Vemurafenib
DETD-35 + Vemurafenib
Cobimetinib + LY3022855 + Vemurafenib
Vemurafenib + Panitumumab + Irinotecan
Vemurafenib + ZSTK474
Vemurafenib + Everolimus
Cetuximab + Selumetinib + Vemurafenib
Navitoclax + Vemurafenib
SAH-p53-8 + Vemurafenib
PX-866 + Vemurafenib
Aldesleukin + Vemurafenib + IFN A2b
Lapatinib + Vemurafenib
Vemurafenib + Carboplatin + Paclitaxel
Atezolizumab + vemurafenib
Onartuzumab + Vemurafenib
PAC-1 + Trametinib + Vemurafenib
Palbociclib + Vemurafenib Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved, in combination with Femara (letrozole), in ER positive, HER2 negative metastatic breast cancer (FDA.gov).
Vemurafenib + Cetuximab
Crizotinib + Vemurafenib
Pembrolizumab + Vemurafenib
PET-16 + Vemurafenib
Vemurafenib + Acitretin
Vemurafenib + Temsirolimus
Selumetinib + Vemurafenib
Vemurafenib + TW-37
Vemurafenib + Tizanidine
CPI-455 + Vemurafenib
Vemurafenib + Cetuximab + Irinotecan
Atezolizumab + Vemurafenib + Cobimetinib
Vemurafenib + Trientine
Vemurafenib + Metformin
XL888 + Vemurafenib
Vemurafenib + SBI-060756
MK2206 + Vemurafenib
Vemurafenib + Interferon alfa-2b
Cobimetinib + XL888 + Vemurafenib
JQ1 + Vemurafenib
Vemurafenib Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of the MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma and for BRAF V600-positive Erdheim-Chester disease (FDA.gov).
Vemurafenib + Voruciclib
PAC-1 + Vemurafenib
Trametinib + Vemurafenib
BEZ235 + Vemurafenib
Vemurafenib + Decitabine
A-1210477 + Vemurafenib
Obinutuzumab + Vemurafenib Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov).
Vemurafenib + Cobimetinib
Cabozantinib + Vemurafenib
Vemurafenib + Gefitinib
CX-072 + Vemurafenib
Pexidartinib + Vemurafenib
Rifampin + Vemurafenib
SAR260301 + Vemurafenib
Onartuzumab + Cobimetinib + Vemurafenib